USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
GENESEGUES, INC.
Address:
GENESEGUES, INC.
3180 HIGH POINT DRIVE
CHASKA, MN 55318-9476
Phone:
N/A
URL:
N/A
EIN:
411955104
DUNS:
95972415
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,211,164.00 9

Award List:

Antisense gene therapy with tumor-targeted nanocapsules

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$245,059.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Antisense oligonucleotides have generated enormous interest as therapeutic molecules since their initial demonstration in 1978, but their full utilization as effective human therapies has been hampered by inadequate drug delivery to the correct cellular… More

S50 nanocapsules for transcutaneous DNA vaccination

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$146,661.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The WHO estimates that 40 million individuals are infected with AIDS worldwide and that 16,000 new infections occur daily, lending continuing support for new approaches in vaccine technology. DNA vaccines offer the advantage over protein vaccines of improved… More

Nanocapsules for transposon therapy in cancer

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$69,883.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Abstract:
Viral vectors are used in more than 70% of current gene therapy trials. However, immunogenicity, oncogenicity, and poor tumor transfection efficiencies present significant barriers to clinical success. Sleeping Beauty Transposon (SBT) technology, combined with a targeted, tumor-penetrating,… More

Tumor-targeted delivery of siRNA via sub-50 nanometer capsules

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$199,475.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The prospect of using siRNAs as potent inhibitors to any gene of choice may provide a new therapeutic approach for many intractable diseases. However, a major impediment to successful development of siRNA-based therapies has been the general inability to deliver… More

SBIR TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUESTOR: ALI ANDALIBI VEN

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$185,073.00
Agency:
HHS
Principal Investigator:
Gretchen Unger
Abstract:
Metastatic spread of cancer cells is the primary cause of death in cancer patients and developing therapeutic agents that kill primary and disseminated cancer cells is an important topic. The aim of this project is to continue the development of a novel na nocapsule for the delivery of RNAi into… More

Nonviral vehicles targeting liver cell-subtypes for nuclear delivery via rafts

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$406,030.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite recent advances, development of nucleic acid (NA) therapies continues to be impeded by the challenges of effective delivery. GeneSegues, Inc. (GSI) has developed a nonviral delivery technology, sub-50 nanometer (s50) capsules, which co-opt the… More

Topical delivery of nanoencapsulated plasmid DNA to posterior ocular targets

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$158,983.00
Agency:
HHS
Principal Investigator:
Gretchen M. Unger – 952-443-3798
Abstract:
DESCRIPTION (provided by applicant): Diseases such as age related macular degeneration (AMD), other retinal dystrophies, and glaucoma cause a large proportion of blindness worldwide. A critical barrier in treating these diseases is the inability to efficaciously, economically, and safely deliver… More

Therapy Management Software for Naturalistic Model-Based Behavioral Interventions

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Gretchen M. Unger – 952-443-3798
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a safe and effective topical vaccine against the dengue virus (DENV). DENV causes an estimated 30 to 50 million cases of debilitating fever leading to over 20,000 deaths worldwide every year. DNA-based vaccines have… More

TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Gretchen Unger – 952-443-3798
Abstract:
The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE